Hornet Therapeutics raised seed funding from 4BIO Capital to develop treatments for EBV-driven pathologies
Hornet Therapeutics raised seed funding from 4BIO Capital to develop treatments for EBV-driven pathologies
05/28/24, 4:24 PM
Location
londonIndustry
biotechnology
Round Type
seed
Investors
4 Bio Capital
Hornet Therapeutics, a London, UK-based biotech company, raised seed funding from 4BIO Capital. The company emerged from stealth with a strategic collaboration and licensing agreement with Kyowa Kirin to develop and commercialize HTX-201 in EBV-related diseases. The amount of the deal was not disclosed.
Company Info
Location
london, england, united kingdom
Additional Info
Hornet Therapeutics is a London, UK-based biotech company focused on developing treatments to address EBV-driven pathologies. The company emerged from stealth with a strategic collaboration and licensing agreement with Kyowa Kirin, enabling them to develop and commercialize HTX-201 in EBV-related diseases.